C3a receptor antagonist therapy is protective with or without thrombolysis in murine thromboembolic stroke.
Saif AhmadChirayu PandyaAdam KindelinKanchan BhatiaRafay ChaudharyAlok Kumar DwivediJennifer M EschbacherQiang LiuMichael F WatersMd Nasrul HodaAndrew F DucruetPublished in: British journal of pharmacology (2020)
We conclude that SB290157 is safe and effective with and without late IVT following TE stroke. Therefore, C3a receptor antagonist therapy represents a promising candidate for clinical translation in stroke, particularly as an adjuvant to IVT.